JP2016514686A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514686A5
JP2016514686A5 JP2016503003A JP2016503003A JP2016514686A5 JP 2016514686 A5 JP2016514686 A5 JP 2016514686A5 JP 2016503003 A JP2016503003 A JP 2016503003A JP 2016503003 A JP2016503003 A JP 2016503003A JP 2016514686 A5 JP2016514686 A5 JP 2016514686A5
Authority
JP
Japan
Prior art keywords
weight
matrix
dosage form
wax
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514686A (ja
JP6466399B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029168 external-priority patent/WO2014144661A1/en
Publication of JP2016514686A publication Critical patent/JP2016514686A/ja
Publication of JP2016514686A5 publication Critical patent/JP2016514686A5/ja
Application granted granted Critical
Publication of JP6466399B2 publication Critical patent/JP6466399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503003A 2013-03-15 2014-03-14 トピラマートの急速分散性の剤形 Active JP6466399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791592P 2013-03-15 2013-03-15
US61/791,592 2013-03-15
PCT/US2014/029168 WO2014144661A1 (en) 2013-03-15 2014-03-14 Rapidly dispersible dosage form of topiramate

Publications (3)

Publication Number Publication Date
JP2016514686A JP2016514686A (ja) 2016-05-23
JP2016514686A5 true JP2016514686A5 (enExample) 2017-04-06
JP6466399B2 JP6466399B2 (ja) 2019-02-06

Family

ID=51537752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503003A Active JP6466399B2 (ja) 2013-03-15 2014-03-14 トピラマートの急速分散性の剤形

Country Status (10)

Country Link
US (2) US9492380B2 (enExample)
EP (1) EP2968181B1 (enExample)
JP (1) JP6466399B2 (enExample)
CN (1) CN105050588B (enExample)
AU (2) AU2014228861B2 (enExample)
CA (1) CA2906172C (enExample)
ES (1) ES2761407T3 (enExample)
HK (1) HK1213473A1 (enExample)
MX (1) MX365914B (enExample)
WO (1) WO2014144661A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
WO2014144512A1 (en) 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CN104586871B (zh) * 2014-12-27 2018-01-16 北京罗诺强施医药技术研发中心有限公司 包含托吡酯的药物组合物
US20160243036A1 (en) * 2015-02-25 2016-08-25 Intelgenx Corp. Film dosage forms containing amorphous active agents
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
JPWO2017175792A1 (ja) * 2016-04-06 2019-02-14 アステラス製薬株式会社 速溶出性三次元造形物、速溶出性三次元造形物用フィラメント及び速溶出性三次元造形物用材料
ES2908220T3 (es) 2016-09-02 2022-04-28 Novo Futura Aps Parrilla desechable y método para fabricar una parrilla desechable
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
CN107213126B (zh) * 2017-05-17 2020-06-23 西安棣加生物科技有限公司 一种3d打印技术制备治疗高磷血症的口腔速崩片的方法
CN107252418B (zh) * 2017-05-17 2020-06-23 西安棣加生物科技有限公司 一种3d打印技术制备治疗低钾血症的口腔速崩片的方法
US10703549B2 (en) * 2017-06-30 2020-07-07 The Procter And Gamble Company Water soluble containers and methods of making them
CA3080975A1 (en) * 2017-11-02 2019-05-09 Zambon S.P.A. Pharmaceutical compositions comprising safinamide
JP7360949B2 (ja) * 2017-12-26 2023-10-13 東和薬品株式会社 環状口腔内崩壊錠
CN111698983B (zh) 2018-01-09 2022-10-18 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
US12544446B2 (en) 2018-03-02 2026-02-10 Vitiprints, LLC Printed delivery device having supplements
AU2019250911B2 (en) * 2018-04-10 2024-10-24 Oneful Health, Inc. Method and system for making personalized nutritional and pharmaceutical formulations using additive manufacturing
JP2022500282A (ja) * 2018-09-14 2022-01-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung コーティングされた固形医薬投薬形態の調製のためのプロセス
KR20250034520A (ko) 2018-10-15 2025-03-11 아프레시아 파마슈티칼즈 엘엘씨 포장 내에 투여 제형을 형성하는 방법 및 시스템
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
CN113490486B (zh) 2019-02-22 2025-10-17 康特伦英国斯温顿捷迪斯有限公司 最小化团聚、曝气和保持包含布洛芬的药物组合物的包衣
BR112021016485A2 (pt) 2019-02-22 2021-10-13 Catalent U.K. Swindon Zydis Limited Minimização de aglomeração de material de revestimento de partícula de fármaco durante armazenamento para estabilizar tempos de desintegração de produtos farmacêuticos
AR118418A1 (es) 2019-02-22 2021-10-06 Catalent Uk Swindon Zydis Ltd Conservación de partículas ifa revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspensión acuosa
CA3129383A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing aeration of suspensions during in-line mixing
AU2020347662B2 (en) * 2019-09-13 2026-07-09 Meiji Co., Ltd. Solid food and solid milk
AU2021296908A1 (en) 2020-06-26 2023-02-16 Aprecia Pharmaceuticals LLC Rapidly-orodispersible tablets having an interior cavity
MX2023001004A (es) 2020-07-31 2023-03-01 Catalent Uk Swindon Zydis Ltd Composiciones farmaceuticas que comprenden un ingrediente farmaceutico activo (api) recubierto.
WO2023200954A1 (en) 2022-04-13 2023-10-19 Aprecia Pharmaceuticals LLC System and method for additive manufacturing using an omnidirectional magnetic movement apparatus
WO2024108082A1 (en) 2022-11-18 2024-05-23 Aprecia Pharmaceuticals LLC Orodispersive dosage forms containing droxidopa
GB2643925A (en) 2024-09-09 2026-03-11 Novumgen Ltd An orodispersible tablet of topiramate and its process of preparation

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US5738875A (en) 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
ES2318869T3 (es) * 1997-02-20 2009-05-01 Massachusetts Institute Of Technology Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion.
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
DE60010464T2 (de) 1999-07-09 2005-05-12 Ortho-Mcneil Pharmaceutical, Inc. Geschmackskaschierte flüssige arzneizubereitungen
AP2002002410A0 (en) * 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
JP5178982B2 (ja) * 2000-05-18 2013-04-10 セリックス, インコーポレイテッド 経口投薬形態における、毒性コアの非毒性領域中へのカプセル化
WO2003097018A1 (en) * 2002-02-04 2003-11-27 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
CA2440069A1 (en) 2001-03-05 2002-09-12 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
JP4845340B2 (ja) * 2001-10-29 2011-12-28 マサチューセッツ インスティテュート オブ テクノロジー 三次元プリント投薬形態のような物品の一軸圧縮のためのシステムおよび方法
CA2463481A1 (en) * 2001-10-29 2003-05-22 Therics, Inc. Three-dimensional suspension printing of dosage forms
FR2838647B1 (fr) 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
CA2497176A1 (en) * 2002-09-04 2004-03-18 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
EP1581197A1 (en) 2002-12-11 2005-10-05 Ranbaxy Laboratories, Limited Coating composition for taste masking coating and methods for their application and use
JP4739217B2 (ja) 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
FR2858556B1 (fr) 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
EP1673064A1 (en) 2003-08-28 2006-06-28 Sandoz AG Pharmaceutical composition comprising anticonvulsant with taste mask coating
JP2007517062A (ja) * 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
WO2006009403A1 (en) * 2004-07-22 2006-01-26 Amorepacific Corporation Sustained-release preparations containing topiramate and the producing method thereof
US20060127479A1 (en) 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US20060182796A1 (en) 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2363113B1 (en) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
AU2008318851B2 (en) * 2007-10-31 2014-04-17 Mcneil-Ppc, Inc. Orally disintegrated dosage form
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
EP2397161B1 (en) 2009-02-12 2019-09-25 Fuji Chemical Industry Co., Ltd. Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same
US20100285130A1 (en) 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
CN102802614A (zh) 2009-06-04 2012-11-28 巴斯夫欧洲公司 含有被遮味活性成分的口腔崩解剂型
JP2013502388A (ja) * 2009-08-19 2013-01-24 バイエル ファーマ アクチエンゲゼルシャフト 小児科の使用のためのドラッグデリバリーシステム(ウェーハ)
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
JP6133009B2 (ja) * 2010-08-11 2017-05-24 協和発酵キリン株式会社 トピラマート顆粒
US9381154B2 (en) * 2011-06-09 2016-07-05 Xerox Corporation Direct inkjet fabrication of drug delivery devices

Similar Documents

Publication Publication Date Title
JP2016513724A5 (enExample)
ES2761407T3 (es) Forma de dosificación rápidamente dispersable de topiramato
JP2018162276A5 (enExample)
JP6040218B2 (ja) 口腔内崩壊錠用直打賦形剤及びその製造方法、並びに口腔内崩壊錠
ES2244167T3 (es) Nuevas preparaciones farmaceuticas multiunitarias estables que contienen bencimidazoles sustituidos.
ES2320438T3 (es) Formulacion farmaceutica oral de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio(s) activo(s).
JP2009512663A5 (enExample)
Kumar et al. Impact of spray drying over conventional surface adsorption technique for improvement in micromeritic and biopharmaceutical characteristics of self-nanoemulsifying powder loaded with two lipophilic as well as gastrointestinal labile drugs
JP2018517735A5 (enExample)
JP5761018B2 (ja) 被覆固形製剤
JP2013540148A (ja) 多粒子状の胃保持型製剤の製造方法
JP2015533164A5 (enExample)
JP7681511B2 (ja) インライン混合中の懸濁液の通気の最小化
JP5160423B2 (ja) 水易溶性薬物含有球状素顆粒の製造方法
CN108633256A (zh) 含水胶囊、以及含水胶囊的制造方法
HK1209371A1 (en) Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
Li et al. Preparation and evaluation of nano-hydroxyapatite/poly (styrene-divinylbenzene) porous microsphere for aspirin carrier
JP6042084B2 (ja) 液状組成物、及びこれを含有する軟カプセル剤
JP6027911B2 (ja) 賦形剤造粒物及びその製造方法、並びに錠剤
JP5454162B2 (ja) フィルムコーティングされた昇華性成分含有固形製剤
CN102970980A (zh) 控制释放的左乙拉西坦配方
JP2011046750A (ja) 口腔内速崩壊性錠
US20040170686A1 (en) Suspension vehicle for coated drug particles
JP6815109B2 (ja) デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物
JP6307874B2 (ja) レイヤリング粒子